Sunday, July 01, 2007

Kinases? Oncogenesis? Tyrosine? What language is this?

Here it is:
For example, the NIAD researchers recently discovered that patients with a particularly aggressive form of the disease have a mutation in c-kit tyrosine kinase; such patients respond spectacularly well to the cancer ‘wonder drug’: imatinib mesylate (Gleevec). However, the most frequent mutations—those in c-kit D816—are relatively resistant to imatinib. “If you don’t find the 816 mutation you can tell parents that their child’s chances are pretty good,” says Metcalfe. The antibiotic geldanamycin (17-AAG), which inhibits Hsp90, is the latest recruit in the fight against mastocytosis as it destabilizes various kinases that are important in oncogenesis.

1 comment:

AbuAmir said...

Well, 17AAG is not exactly geldanamycin. It is an improved version of it, less damaging the patient's liver.